BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20182874)

  • 21. Allogeneic class I MHC requirement for alloantigen-reactive helper T-lymphocyte responses in vivo. Evidence for indirect presentation of alloantigen.
    Clement JD; Chan SY; Bishop DK
    Transplantation; 1996 Aug; 62(3):388-96. PubMed ID: 8779688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy.
    Suda T; Tsunoda T; Daigo Y; Nakamura Y; Tahara H
    Cancer Sci; 2007 Nov; 98(11):1803-8. PubMed ID: 17784873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells.
    Schroers R; Huang XF; Hammer J; Zhang J; Chen SY
    Cancer Res; 2002 May; 62(9):2600-5. PubMed ID: 11980655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes.
    Schroers R; Shen L; Rollins L; Rooney CM; Slawin K; Sonderstrup G; Huang XF; Chen SY
    Clin Cancer Res; 2003 Oct; 9(13):4743-55. PubMed ID: 14581345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response.
    Zhou G; Ding ZC; Fu J; Levitsky HI
    J Immunol; 2011 Feb; 186(4):2148-55. PubMed ID: 21242518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy.
    Teramoto K; Ohshio Y; Fujita T; Hanaoka J; Kontani K
    J Cancer Res Clin Oncol; 2013 May; 139(5):861-70. PubMed ID: 23411688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Flexibility in MHC and TCR recognition: degenerate specificity at the T cell level in the recognition of promiscuous Th epitopes exhibiting no primary sequence homology.
    Joshi SK; Suresh PR; Chauhan VS
    J Immunol; 2001 Jun; 166(11):6693-703. PubMed ID: 11359825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles.
    Nisini R; Paroli M; Accapezzato D; Bonino F; Rosina F; Santantonio T; Sallusto F; Amoroso A; Houghton M; Barnaba V
    J Virol; 1997 Mar; 71(3):2241-51. PubMed ID: 9032359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitope.
    Kallinteris NL; Wu S; Lu X; Humphreys RE; von Hofe E; Xu M
    J Immunother; 2005; 28(4):352-8. PubMed ID: 16000953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of EXP1-Specific CD4+ T Cell Responses Directed Against a Broad Range of Epitopes Including Two Promiscuous MHC Class II Binders During Acute
    Heide J; Wildner NH; Ackermann C; Wittner M; Marget M; Sette A; Sidney J; Jacobs T; Schulze Zur Wiesch J
    Front Immunol; 2019; 10():3037. PubMed ID: 32038611
    [No Abstract]   [Full Text] [Related]  

  • 31. Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses.
    Matsuzaki J; Tsuji T; Luescher IF; Shiku H; Mineno J; Okamoto S; Old LJ; Shrikant P; Gnjatic S; Odunsi K
    Sci Rep; 2015 Oct; 5():14896. PubMed ID: 26447332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Attenuated Listeria monocytogenes carrier strains can deliver an HIV-1 gp120 T helper epitope to MHC class II-restricted human CD4+ T cells.
    Guzmán CA; Saverino D; Medina E; Fenoglio D; Gerstel B; Merlo A; Li Pira G; Buffa F; Chakraborty T; Manca F
    Eur J Immunol; 1998 Jun; 28(6):1807-14. PubMed ID: 9645361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of promiscuous HLA-DR-restricted CD4⁺ T-cell epitopes on the cancer-testis antigen HCA587.
    Wen W; Zhang L; Peng J; Chen J; Hao J; Li X; Qian X; Zeng P; Zhang Y; Yin Y
    Cancer Sci; 2011 Aug; 102(8):1455-61. PubMed ID: 21595801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes.
    Kobayashi H; Ngato T; Sato K; Aoki N; Kimura S; Tanaka Y; Aizawa H; Tateno M; Celis E
    Clin Cancer Res; 2006 Jun; 12(12):3814-22. PubMed ID: 16778109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peptide epitope identification for tumor-reactive CD4 T cells.
    Kobayashi H; Celis E
    Curr Opin Immunol; 2008 Apr; 20(2):221-7. PubMed ID: 18499419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53.
    Kumai T; Ishibashi K; Oikawa K; Matsuda Y; Aoki N; Kimura S; Hayashi S; Kitada M; Harabuchi Y; Celis E; Kobayashi H
    Cancer Immunol Immunother; 2014 May; 63(5):469-78. PubMed ID: 24633296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors.
    Ossendorp F; Mengedé E; Camps M; Filius R; Melief CJ
    J Exp Med; 1998 Mar; 187(5):693-702. PubMed ID: 9480979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes.
    Wilson CC; Palmer B; Southwood S; Sidney J; Higashimoto Y; Appella E; Chesnut R; Sette A; Livingston BD
    J Virol; 2001 May; 75(9):4195-207. PubMed ID: 11287569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways.
    Pouniotis DS; Esparon S; Apostolopoulos V; Pietersz GA
    Immunol Cell Biol; 2011 Nov; 89(8):904-13. PubMed ID: 21383765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
    Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
    Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.